- Home
- SPRY vs BBNX Comparison
SPRY vs BBNX Comparison
Compare SPRY & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPRY
- BBNX
- Stock Information
- Founded
- SPRY 2015
- BBNX 2015
- Country
- SPRY United States
- BBNX United States
- Employees
- SPRY 24
- BBNX N/A
- Industry
- SPRY Biotechnology: Pharmaceutical Preparations
- BBNX Medical/Dental Instruments
- Sector
- SPRY Health Care
- BBNX Health Care
- Exchange
- SPRY Nasdaq
- BBNX Nasdaq
- Market Cap
- SPRY 1.2B
- BBNX 866.3M
- IPO Year
- SPRY N/A
- BBNX 2025
- Fundamental
- Price
- SPRY $11.95
- BBNX $14.04
- Analyst Decision
- SPRY Strong Buy
- BBNX Strong Buy
- Analyst Count
- SPRY 5
- BBNX 6
- Target Price
- SPRY $26.80
- BBNX $26.67
- AVG Volume (30 Days)
- SPRY 1.3M
- BBNX 336.5K
- Earning Date
- SPRY 03-20-2025
- BBNX 05-06-2025
- Dividend Yield
- SPRY N/A
- BBNX N/A
- EPS Growth
- SPRY N/A
- BBNX N/A
- EPS
- SPRY N/A
- BBNX N/A
- Revenue
- SPRY $2,568,000.00
- BBNX $53,034,000.00
- Revenue This Year
- SPRY $61,233.33
- BBNX $451.69
- Revenue Next Year
- SPRY $585.54
- BBNX $31.17
- P/E Ratio
- SPRY N/A
- BBNX N/A
- Revenue Growth
- SPRY 8460.00
- BBNX 6601.12
- 52 Week Low
- SPRY $7.55
- BBNX $13.64
- 52 Week High
- SPRY $18.51
- BBNX $24.50
- Technical
- Relative Strength Index (RSI)
- SPRY 55.76
- BBNX N/A
- Support Level
- SPRY $10.00
- BBNX N/A
- Resistance Level
- SPRY $11.55
- BBNX N/A
- Average True Range (ATR)
- SPRY 0.69
- BBNX 0.00
- MACD
- SPRY 0.21
- BBNX 0.00
- Stochastic Oscillator
- SPRY 78.00
- BBNX 0.00
About SPRY ARS Pharmaceuticals Inc.
ARS Pharmaceuticals Inc is a biopharmaceutical company focused on the development of novel, potentially first-in-class product candidate, neffy for the emergency treatment of Type I allergic reactions, including anaphylaxis. neffy is a proprietary composition of epinephrine with an absorption enhancer called Intravail, which allows neffy to provide injection-like absorption of epinephrine at a low dose, in a small, easy-to-carry, easy-to-use, rapidly administered and reliable nasal spray.
About BBNX Beta Bionics Inc. Common Stock
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company product include the iLet Bionic Pancreas (iLet). The Company operates as single segment, focused on the development, manufacture and sale of the iLet.